生物医药企业Repare Therapeutics（RPTX.O）股价在盘后交易时段劲扬18%至1.68美元，此前该公司宣布与瑞士私营制药企业Debiopharm达成全球授权协议。根据协议条款，Repare将旗下抗癌药物lunresertib的全球开发和商业化权益授予Debiopharm，并即刻获得1000万美元预付款。
该交易潜在价值高达2.57亿美元，包含后续里程碑付款及销售分成。值得注意的是，Debiopharm计划将lunresertib与其自主研发的抗癌药物Debio 0123组成联合疗法进行临床开发，此举有望提升两种药物的协同治疗效果。
受此消息提振，Repare Therapeutics今年迄今累计涨幅扩大至9.2%。此次战略合作不仅加速了lunresertib的全球化进程，也为公司管线药物商业化注入强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.